These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 18192008)

  • 1. Bortezomib is able to reduce angiogenesis in half of patients affected by idiopathic myelofibrosis: an ex vivo study.
    Galimberti S; Canestaro M; Ciancia E; Fazzi R; Marasca R; Petrini M
    Leuk Res; 2008 Aug; 32(8):1324-5. PubMed ID: 18192008
    [No Abstract]   [Full Text] [Related]  

  • 2. Bortezomib therapy in myelofibrosis: a phase II clinical trial.
    Mesa RA; Verstovsek S; Rivera C; Pardanani A; Hussein K; Lasho T; Wu W; Tefferi A
    Leukemia; 2008 Aug; 22(8):1636-8. PubMed ID: 18305559
    [No Abstract]   [Full Text] [Related]  

  • 3. Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib.
    Anargyrou K; Terpos E; Vassilakopoulos TP; Pouli A; Sachanas S; Tzenou T; Masouridis S; Christoulas D; Angelopoulou MK; Dimitriadou EM; Kalpadakis C; Tsionos K; Panayiotidis P; Dimopoulos MA; Pangalis GA; Kyrtsonis MC;
    Haematologica; 2008 Mar; 93(3):451-4. PubMed ID: 18287135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib (PS-341) in patients with human herpesvirus 8-associated primary effusion lymphoma.
    Boulanger E; Meignin V; Oksenhendler E
    Br J Haematol; 2008 May; 141(4):559-61. PubMed ID: 18341641
    [No Abstract]   [Full Text] [Related]  

  • 5. Bortezomib in the front-line treatment of multiple myeloma.
    Richardson PG; Mitsiades C; Schlossman R; Ghobrial I; Hideshima T; Munshi N; Anderson KC
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1053-72. PubMed ID: 18588451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib-mediated proteasome inhibition as a potential strategy for the treatment of rhabdomyosarcoma.
    Bersani F; Taulli R; Accornero P; Morotti A; Miretti S; Crepaldi T; Ponzetto C
    Eur J Cancer; 2008 Apr; 44(6):876-84. PubMed ID: 18342500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to bortezomib in refractory type I cryoglobulinemia.
    Talamo G; Claxton D; Tricot G; Fink L; Zangari M
    Am J Hematol; 2008 Nov; 83(11):883-4. PubMed ID: 18756542
    [No Abstract]   [Full Text] [Related]  

  • 8. Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma.
    Zangari M; Guerrero J; Cavallo F; Prasad HK; Esseltine D; Fink L
    Haematologica; 2008 Jun; 93(6):953-4. PubMed ID: 18515882
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myeloma.
    Dawson MA; Opat SS; Taouk Y; Donovan M; Zammit M; Monaghan K; Horvath N; Roberts AW; Prince HM; Hertzberg M; McLean CA; Spencer A
    Clin Cancer Res; 2009 Jan; 15(2):714-22. PubMed ID: 19147779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous proteosome inhibition and heat shock protein induction by bortezomib is beneficial in experimental pancreatitis.
    Szabolcs A; Biczó G; Rakonczay Z; Tiszlavicz L; Halm G; Wittmann T; Takács T
    Eur J Pharmacol; 2009 Aug; 616(1-3):270-4. PubMed ID: 19486901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent radiation therapy and bortezomib in myeloma patient.
    Berges O; Decaudin D; Servois V; Kirova YM
    Radiother Oncol; 2008 Feb; 86(2):290-2. PubMed ID: 18199515
    [No Abstract]   [Full Text] [Related]  

  • 12. Bortezomib and liposomal doxorubicin are highly effective in obtaining the best possible response before autologous transplant for multiple myeloma.
    Buda G; Orciuolo E; Galimberti S; Cecconi N; Petrini M
    Acta Haematol; 2009; 122(1):39-41. PubMed ID: 19729887
    [No Abstract]   [Full Text] [Related]  

  • 13. Thalidomide therapy in compensated and decompensated myelofibrosis with myeloid metaplasia.
    Pozzato G; Zorat F; Nascimben F; Comar C; Kikic F; Festini G
    Haematologica; 2001 Jul; 86(7):772-3. PubMed ID: 11454539
    [No Abstract]   [Full Text] [Related]  

  • 14. Cutaneous myeloma and bortezomib.
    Gozzetti A; Defina M; Bocchia M
    Ann Hematol; 2009 Oct; 88(10):1045. PubMed ID: 19597817
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of bortezomib on human neuroblastoma cells in vitro and in a metastatic xenograft model.
    Valentiner U; Haane C; Nehmann N; Schumacher U
    Anticancer Res; 2009 Apr; 29(4):1219-25. PubMed ID: 19414367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
    Aghajanian C; Blessing JA; Darcy KM; Reid G; DeGeest K; Rubin SC; Mannel RS; Rotmensch J; Schilder RJ; Riordan W;
    Gynecol Oncol; 2009 Nov; 115(2):215-20. PubMed ID: 19712963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series.
    Wolf J; Richardson PG; Schuster M; LeBlanc A; Walters IB; Battleman DS
    Clin Adv Hematol Oncol; 2008 Oct; 6(10):755-60. PubMed ID: 18997666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Spigel DR; Barton J; Farley C; Schreeder M; Hon J; Greco FA
    Cancer; 2008 Aug; 113(4):765-71. PubMed ID: 18543319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.
    Lonial S; Richardson PG; San Miguel J; Sonneveld P; Schuster MW; Bladé J; Cavenagh J; Rajkumar SV; Jakubowiak AJ; Esseltine DL; Anderson KC; Harousseau JL
    Br J Haematol; 2008 Oct; 143(2):222-9. PubMed ID: 18713253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A striking response to bortezomib in a patient with pleural localization of multiple myeloma.
    Mangiacavalli S; Varettoni M; Zappasodi P; Pica G; Lazzarino M; Corso A
    Leuk Res; 2009 Apr; 33(4):577-8. PubMed ID: 18842298
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.